Sun Pharma and BMS lead 2025 ANDA litigation

According to new research, generic and brand-name pharma companies are ramping up ANDA litigation with Sun Pharma and Bristol Myers Squibb leading the charge.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Americas

Gilead blocks HIV drug generics for more than 10 years

9 October 2025 The pharma giant extends market exclusivity for a top-selling drug accounting for nearly half of its multi-billion-dollar sales.

Americas

Teva draws line under asthma inhaler feud with US rival

31 July 2025 Settlement ends expectations of SCOTUS petition | Federal Circuit stipulates patents must explicitly claim the active ingredient of a drug to qualify for Orange Book listing | FTC backs Amneal, saying ‘improper listings’ stifle generic competition.

Big Pharma

AstraZeneca defends diabetes medications in triple lawsuits

7 December 2023 The UK pharmaceutical company filed three lawsuits against Sun Pharma | Sun’s abbreviated new drug application for generic versions of diabetes medications sparks fightback.

More features

Weil continues IP expansion as another litigator jumps from rival firm

WIPR Rankings reveals the go-to firms and attorneys for China patent work

Pfizer can’t block Novo Nordisk’s $10bn takeover deal

WBD adds litigation firepower in Silicon Valley with DLA Piper veteran

New AIPLA president calls for greater certainty in US patent law

Regeneron and CureVac: UPC ‘cannot be ignored’

US generics company wins patent battle over Merck Serono’s blockbuster MS drug

Novartis counsel warns: ‘Don’t let AI develop without our input’

Sun Pharma and BMS lead 2025 ANDA litigation

More on this story

Editor's picks

Editor's picks

More features